|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||14.37 - 14.65|
|52 Week Range||10.20 - 18.30|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||7.57|
|Forward Dividend & Yield||0.53 (3.56%)|
|Ex-Dividend Date||Jun 14, 2021|
|1y Target Est||N/A|
Drugmaker Mundipharma has included Boyu Capital and state-owned Sinopharm on a shortlist of bidders for its Chinese business, two people familiar with the situation said. Chinese buyout firms CITIC Capital and CPE are also on the shortlist for Mundipharma's China unit, which sources have said could fetch more than $1 billion.
The United Arab Emirates and Bahrain have made the Pfizer/BioNTech coronavirus vaccine available as a booster shot to those initially immunised with a vaccine developed by the China National Pharmaceutical Group (Sinopharm). The Gulf states, which have vaccinated large portions of their populations, initially started inoculating residents and citizens with the Sinopharm COVID-19 shot before later introducing other vaccines.
Two COVID-19 vaccines from China's state-run Sinopharm have shown more than 70% efficacy against symptomatic cases, according to the first detailed results of a large late-stage study. The two inactivated vaccines developed by China National Biotec Group, a subsidiary of Sinopharm , were found to be 72.8% and 78.1% effective against symptomatic COVID-19, based on findings from the Phase 3 trial. The peer-reviewed study were published in the Journal of the American Medical Association on May 26. The results combined findings from trials in the United Arab Emirates, Bahrain, Egypt and Jordan including a total of 40,832 volunteers. Earlier this month, the World Health Organization granted emergency use authorization for the Sinopharm vaccine.